Comprehensive genomic profiling of advanced penile carcinoma suggests a high frequency of clinically relevant genomic alterations

Oncologist

Volumn 21, Issue 1, 2015, Pages 33-39

  Ali, Siraj M ^a   Pal, Sumanta K ^b   Wang, Kai ^a   Palma, Norma A ^a   Sanford, Eric ^a   Bailey, Mark ^a   He, Jie ^a   Elvin, Julia A ^a   Chmielecki, Juliann ^a   Squillace, Rachel ^a   Dow, Edward ^a   Morosini, Deborah ^a   Buell, Jamie ^a   Yelensky, Roman ^a   Lipson, Doron ^a   Frampton, Garrett M ^a   Howley, Peter ^c   Ross, Jeffrey S ^a,d   Stephens, Philip J ^a   Miller, Vincent A ^a  

^a FOUNDATION MEDICINE   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; BRCA2 PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; E1A ASSOCIATED P300 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 4; FIBROBLAST GROWTH FACTOR 10; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 3; FIBROBLAST GROWTH FACTOR 4; JANUS KINASE 2; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROTEIN MCL 1; PROTEIN MLH1; PROTEIN MSH6; PROTEIN P53; SCATTER FACTOR; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR SOX2; UNINDEXED DRUG; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; NOTCH1 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; AT RICH INTERACTIVE DOMAIN 2 GENE; CLINICAL ARTICLE; COMPREHENSIVE GENOMIC PROFILING; CONTROLLED STUDY; DNA EXTRACTION; F BOX AND WD REPEAT DOMAIN CONTAINING 7 GENE; FAT TUMOR SUPPRESSOR HOMOLOG 1 GENE; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION PROFILING; GENE INSERTION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; NUCLEAR FACTOR ERYTHROID 2 LIKE 2 GENE; ONCOGENE H RAS; PENILE SQUAMOUS CELL CARCINOMA; PENIS CARCINOMA; POINT MUTATION; PRIORITY JOURNAL; RAPAMYCIN INSENSITIVE COMPANION OF MTOR GENE; TUMOR GENE; VERY ELDERLY; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; EXON; GENE EXPRESSION REGULATION; GENETICS; HIGH THROUGHPUT SEQUENCING; MUTATION; PATHOLOGY; PENILE NEOPLASMS;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; EXONS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM STAGING; PENILE NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, NOTCH1;

EID: 84955310347     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0241     Document Type: Article

References (29)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5–29.
2. Graafland NM, Verhoeven RH, Coebergh JW et al. Incidence trends and survival of penile squamous cell carcinoma in the Netherlands. Int J Cancer 2011; 128: 426–432.
3. NCCN Clinical Practice Guidelines in Oncology: Penile Cancer (version 3. 2015). Available at http://www.nccn.org. Accessed March 19, 2015.
4. Pagliaro LC, Williams DL, Daliani D et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: A phase II study. J Clin Oncol 2010; 28: 3851–3857.
5. Pizzocaro G, Algaba F, Horenblas S et al. EAU penile cancer guidelines 2009. Eur Urol 2010; 57: 1002–1012.
6. Brown A, Ma Y, Danenberg K et al. Epidermal growth factor receptor-targeted therapy in squamous cell carcinomaof the penis: Areportof 3cases. Urology 2014; 83: 159–165.
7. Carthon BC, Ng CS, Pettaway CA et al. Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis. BJU Int 2014; 113: 871–877.
8. Rescigno P, Matano E, Raimondo L et al. Combination ofdocetaxel and cetuximab for penile cancer: A case report and literature review. Anticancer Drugs 2012; 23: 573–577.
9. de Sousa ID, Vidal FC, Branco Vidal JP et al. Prevalence of human papillomavirus in penile malignant tumors: viral genotyping and clinical aspects. BMC Urol 2015; 15: 13.
10. Faraj SF, Chaux A, Gonzalez-Roibon N et al. Immunohistochemical expression of ARID1A in penile squamous cell carcinomas: A tissue microarray study of 112 cases. Hum Pathol 2015; 46: 761–766.
11. Fonseca AG, Soares FA, Burbano RR et al. Human papilloma virus: Prevalence, distribution and predictive value to lymphatic metastasis in penile carcinoma. Int Braz J Urol 2013; 39: 542–550.
12. Heideman DA, Waterboer T, Pawlita M et al. Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma. J Clin Oncol 2007; 25: 4550–4556.
13. Kirrander P, Kolaric A, Helenius G et al. Human papillomavirus prevalence, distribution and correlation to histopathological parameters in a large Swedish cohort of men with penile carcinoma. BJU Int 2011; 108: 355–359.
14. Madsen BS, van den Brule AJ, Jensen HL et al. Risk factors for squamous cell carcinoma of the penis: Population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev 2008; 17: 2683–2691.
15. Barzon L, Cappellesso R, Peta E et al. Profiling of expression of human papillomavirus-related cancer miRNAs in penile squamous cell carcinomas. Am J Pathol 2014; 184: 3376–3383.
16. Busso-Lopes AF, Marchi FA, Kuasne H et al. Genomic profiling of human penile carcinoma predicts worse prognosis and survival. Cancer Prev Res (Phila) 2015; 8: 149–156.
17. Douillard JY, Oliner KS, Siena S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023–1034.
18. Loi S, Michiels S, Baselga J et al. PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor–positive breast cancer. PLoS One 2013; 8: e53292.
19. Villaruz LC, Socinski MA. Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7 mutation. Lung Cancer 2014; 83: 300–301.
20. Leontieva OV, Blagosklonny MV. CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: Duration of cell cycle arrest and MTOR activity determine geroconversion. Cell Cycle 2013; 12: 3063–3069.
21. Finn RS, Crown JP, Lang I et al. The cyclindependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptorpositive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet Oncol 2015; 16: 25–35.
22. Cen L, Carlson BL, Schroeder MA et al. p16-Cdk4-Rb axis controls sensitivity to a cyclindependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro Oncol 2012; 14: 870–881.
23. Logan JE, Mostofizadeh N, Desai AJ et al. PD-0332991, a potent and selective inhibitor of cyclindependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity. Anticancer Res 2013; 33: 2997–3004.
24. Young RJ, Waldeck K, Martin C et al. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. Pigment Cell Melanoma Res 2014; 27: 590–600.
25. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: Perspectives for new targeted therapeutics. Nat Rev Cancer 2007; 7: 750–762.
26. Ojesina AI, Lichtenstein L, Freeman SS et al. Landscape of genomic alterations in cervical carcinomas. Nature 2014; 506: 371–375.
27. Sanford EM, Ali SM, Elvin JA et al. Comprehensive genomic profiling of anal squamous cell carcinoma reveals high frequency of clinically relevant genomic alterations in the pi3k/mtor pathway. J Clin Oncol 2015; 36: 148139a.
28. Elvin JA, Bailey M, Carneiro BA et al. Comprehensive genomic profiling of cervical squamous cell carcinoma identifies targeted therapy options. J Clin Oncol 2015; 36: 152788a.
29. Chaux A, Velazquez EF, Barreto JE et al. New pathologic entities in penile carcinomas: An update of the 2004 World Health Organization classification. Semin Diagn Pathol 2012; 29: 59–66.